Females with germline mutations in BRCA1 are predisposed to develop breast and ovarian cancers. A previous report indicated that BRCA1 colocalizes with and is necessary for the correct localization of XIST, a noncoding RNA that coats the inactive X chromosome (Xi) to mediate formation of facultative heterochromatin. A model emerged from this study suggesting that loss of BRCA1 in female cells could reactivate genes on the Xi through loss of the XIST RNA. However, our independent studies of BRCA1 and XIST RNA revealed little evidence to support this model. We report that BRCA1 is not enriched on XIST RNA-coated chromatin of the Xi. Neither mutation nor depletion of BRCA1 causes significant changes in XIST RNA localization or X-linked gene expression. Together, these results do not support a role for BRCA1 in promoting XIST RNA localization to the Xi or regulating XIST-dependent functions in maintaining the stability of facultative heterochromatin.
INTRODUCTION
Mutations in breast cancer-associated gene 1 (BRCA1) are associated with hereditary breast and ovarian cancers (Alberg et al., 1999; Brody and Biesecker, 1998) . BRCA1 encodes a ubiquitin ligase that acts in checkpoint and DNA damage-repair pathways to ensure genome integrity (Deng, 2006; Venkitaraman, 2002) . In addition, BRCA1 plays a role in meiotic XY inactivation (Turner et al., 2004) . BRCA1 has also been implicated in regulation of somatic cell X inactivation, leading to the suggestion that loss of BRCA1 in female cells may lead to Xi perturbation and destabilization of its silenced state (Ganesan et al., 2002) . This finding has impacted both the breast cancer and X inactivation research communities.
In female mammals, one X chromosome is silenced in each cell to achieve equivalent X-linked gene dosage between females and males. X inactivation occurs early in mammalian embryogenesis, and in the mouse, the Xist gene is essential for the initiation of X chromosome silencing (Marahrens et al., 1997; Penny et al., 1996) . When X inactivation is initiated, Xist RNA spreads from its site of transcription to coat the X chromosome, and this cisspread correlates with the initial transcriptional silencing of the Xi Sheardown et al., 1997) . During the maintenance phase of X inactivation, an accumulation of XIST RNA coats the Xi in somatic cells (Brown et al., 1992) . Deletion of the XIST/Xist gene in somatic cells does not result in complete reactivation of the Xi (Brown and Willard, 1994; Csankovszki et al., 2001) . Instead, there is stochastic and infrequent gene reactivation, indicating that Xist acts with other factors to maintain silencing of the Xi (Csankovszki et al., 2001) . Ganesan et al. (2002) presented several lines of evidence implicating BRCA1 in regulation of X inactivation. First, BRCA1 was enriched with the XIST RNA-coated chromatin of the Xi in female cells. Second, localized XIST RNA was not detected in BRCA1 mutant tumors and cell lines. Third, when wild-type BRCA1 was used to reconstitute a BRCA1-deficient cell line, XIST RNA was detected in a pattern consistent with its association with an Xi chromosome. Fourth, XIST RNA was no longer detected on the Xi when BRCA1 was depleted by RNA interference (RNAi). Fifth, while XIST RNA was not detected in BRCA1 À/À tumors, it was correctly localized in BRCA1-positive sporadic breast cancer samples. Finally, knockdown of BRCA1 activated expression of an Xi-linked GFP, consistent with a role in maintaining X inactivation. Together, these results suggested that BRCA1 contributes to the stable silencing of X-linked genes by regulating the localization of XIST RNA. These findings were significant because BRCA1 was the first factor implicated as playing a role in XIST RNA localization and because they provided a possible mechanism by which loss of BRCA1 could contribute to cancer progression. However, our independent studies to extend the findings of Ganesan et al. (2002) indicate that BRCA1 does not regulate XIST RNA. We report that BRCA1 does not colocalize with XIST RNA in any cell type assayed. Reconstitution of BRCA1 in BRCA1 mutant cell lines does not affect XIST RNA distribution. Depletion of BRCA1 in wildtype cells does not alter XIST RNA localization. In mouse tumor cells mutant for Brca1, Xist RNA exhibits a normal distribution in 11 of 14 primary tumor lines. A human breast cancer cell line expressing mutant BRCA1 also shows normal XIST RNA distribution in the majority of cells. Finally, dosage compensation in mouse Brca1 mutant embryos and adult mammary tissues is normal. In combination, these results do not support a role for BRCA1 in regulation of XIST RNA localization or its function in X inactivation.
RESULTS
Localization of BRCA1 Relative to the Xi BRCA1 was previously reported to colocalize with XIST RNA on the Xi in several different human female somatic cell types (Ganesan et al., 2002) . However, only a subset of cells in asynchronous populations displayed near perfect overlap of BRCA1 and XIST (5%-10%), suggesting that BRCA1 recruitment to the Xi may be transient. We tested whether the frequency of BRCA1 association with the Xi might differ in cell populations initiating X inactivation versus cells in the maintenance phase of X inactivation. However, when we examined cells in the earliest stages of X inactivation and two terminally differentiated cell types, we did not detect significant overlap between BRCA1 and the Xi in any developmental context (see Figure S1 in the Supplemental Data available with this article online).
These data prompted us to characterize localization of BRCA1 in the human cell types that were reported to show BRCA1/XIST RNA colocalization (HMEC-t, IMR-90, and WI-38), using the same monoclonal antibodies and fixation conditions (Experimental Procedures; Ganesan et al., 2002) . Consistent with previous studies of human somatic cell Xi structure, the histone variant macroH2A1 and XIST RNA showed significant overlap coincident with the Barr body ( Figure 1A ; Clemson et al., 1996; Costanzi and Pehrson, 1998) . In contrast, when we compared BRCA1 localization relative to XIST RNA, we observed three general patterns of localization in all cell lines and with all antibodies tested, none of which were consistent with BRCA1 ''coating'' the XIST RNA-enriched component of the Xi (Figures 1B-1D ; Figure S2 ; Table S1). For example, in WI-38 cells, the vast majority (98%) of cells staining positive for BRCA1 showed small discrete foci distributed throughout the nucleus (Scully et al., 1997a (Scully et al., , 1997b , with no apparent spatial relationship with the Xi ( Figure 1B ; Table S1 ). In a small percentage (1.9%) of cells, one small BRCA1 nuclear focus appeared closely apposed to the XIST RNA signal yet did not overlap with the XIST RNA ( Figure 1C ). Only in rare cases did BRCA1 display a patchy appearance near XIST RNA (<0.1%; Figures 1D and 1E) ; however, even in these events, BRCA1 still appeared to be largely nonoverlapping with the XIST RNA signal. In sum, BRCA1 abutted XIST RNA or showed only minimal overlap in <3% of cells in all cell types examined. Whereas Ganesan et al. reported a 5%-10% frequency of significant BRCA1/XIST RNA overlap, comparable to the overlap seen for macroH2A1 and XIST RNA ( Figure 1A ), we observed a 0% frequency of this class of events.
We also examined the distribution of BRCA1 relative to the Xi in cells labeled with BrdU or PCNA ( Figure S3 ), as a recent study indicated that cells showing BRCA1 enrichment near the Xi are in late S phase when the Xi is replicating (Chadwick and Lane, 2005) . However, even cells in late S phase revealed only a limited spatial relationship between BRCA1 and the Xi.
These data indicate that BRCA1 does not coat the XIST RNA-enriched component of the Xi in female somatic cells. This stands in contrast to the BRCA1 distribution on the XY chromosomes observed in male pachytene spermatocytes ( Figure 1F ), where BRCA1 localizes along the entire surface of unsynapsed XY chromosome axes (Turner et al., 2004) . This difference may reflect the finding that meiotic XY silencing proceeds by a mechanism involving silencing of unsynapsed DNA (Turner et al., 2006) , which is distinct from X chromosome inactivation in somatic cells.
Analysis of XIST RNA in a BRCA1-Deficient Cell Line Analysis of BRCA1-deficient cells suggested a role for this tumor-suppressor protein in localization of XIST RNA to the Xi (Ganesan et al., 2002) . The BRCA1-deficient HCC1937 human female breast cancer cell line contains a nonsense BRCA1 mutation that results in production of a truncated, unstable protein (Scully et al., 1999; Tomlinson et al., 1998) . Although HCC1937 cells were shown to express near wild-type levels of XIST RNA, they lacked the appearance of an X chromosome coated by the XIST RNA, as well as other features of Xi heterochromatin (Ganesan et al., 2002) . Reconstitution of wild-type BRCA1 in this line was reported to restore XIST staining without affecting the steady-state levels of XIST RNA (Ganesan et al., 2002) .
First, we analyzed XIST RNA localization in two different samples of parental HCC1937 cells obtained independently from American Type Culture Collection (ATCC). Three patterns of XIST RNA localization were observed: no detectable XIST RNA, a pinpoint XIST RNA signal, and XIST RNA accumulations that were smaller and more dispersed than those seen in wild-type fibroblasts (Figures 2A and 2B ). Both samples differed in the proportion of cells exhibiting each pattern ( Figure 2D ). These results indicate that there is considerable variability in the distribution of XIST RNA among the vials of commercially available HCC1937 cells, which complicates analysis of cell lines derived from HCC1937 cells.
Next, we compared the distribution of XIST RNA in independently obtained pairs of HCC1937 cell lines carrying either wild-type BRCA1 in a retroviral vector or empty vector ( Figure S4 ; Scully et al., 1999; Zhang et al., 2004) . In all four lines, cells exhibited either a pinpoint of XIST RNA or no detectable XIST RNA ( Figure 2C) cell populations were analyzed by BRCA1 immunofluorescence and Xist RNA-FISH (green and red, respectively, in Figure 2E ). BRCA1 protein levels in transfected cell populations were monitored by western blot analysis ( Figure 2F ). In 490 BRCA1-positive cells scored among the three different Brca1 D11/D11 -transfected cell populations, none had an Xist RNA signal of any sort. Thus, in agreement with our analysis of HCC1937 cells, reconstitution of murine BRCA1 in BRCA1-deficient mouse mammary tumor cell lines failed to elicit significant effects on Xist RNA abundance or localization.
In normal female cells, unspliced XIST transcripts appear as a pinpoint FISH signal at the XIST locus, in contrast to mature, spliced XIST RNA, which coats the Xi (Clemson et al., 1996) . Spliced XIST RNA was not detected in HCC1937+BRCA1
WT or HCC1937+vector cells using quantitative real-time RT-PCR (data not shown). Using primers that detect spliced and unspliced XIST RNA, steady-state levels of total XIST RNA were several orders of magnitude lower in HCC1937+vector and HCC1937+ BRCA1 WT cells than in wild-type female fibroblasts (3600-fold and 700-fold; Figure 2G ), consistent with only nascent XIST transcripts being produced in these HCC1937 derivative lines. Recently, it was found that HCC1937 cells, like many cancer cell lines, show loss of X chromosome heterozygosity and markers of Xi chromatin, consistent with loss of the Xi (Sirchia et al., 2005) . Therefore, the XIST RNA pinpoint staining observed in HCC1937 and derivative lines represents low-level, spurious XIST expression from an Xa. We conclude that BRCA1 reconstitution in HCC1937 cells does not rescue a localization defect for XIST RNA.
XIST RNA Association with the Xi Persists after BRCA1 RNA Interference We examined whether acute knockdown of BRCA1 impacted XIST localization in cells containing a bona fide XIST-expressing Xi. Lentiviral infection was used to transduce telomerase-immortalized human mammary epithelial cells (HMEC-t) with either empty vector or a plasmid expressing a shRNA to BRCA1. While an average of 62% of HMEC-t cells stably transfected with empty vector exhibited positive staining for BRCA1, only 7% of HMEC-t cells stably expressing the BRCA1 shRNA stained positive for BRCA1, indicating significant depletion of BRCA1 in most cells (Figures 3A and 3B) . Western blot analysis of both cell populations confirmed that 80% of total BRCA1 protein levels had been depleted in BRCA1 shRNA-expressing cells relative to control cell populations ( Figure 3C specific for BRCA1 (85% depletion; Figures 3G-3I ), and in IMR-90 cells ( Figure S5 ). Therefore, the XIST/Xist transcript remains abundant and can coat the Xi despite significant depletion of BRCA1.
Xist RNA Accumulates on the Xi in Murine Brca1 Mutant Tumors One example of a Brca1 mutation reported to correlate with Xist RNA mislocalization was the deletion of exon 11: two murine Brca1 D11/D11 tumor cell lines completely lacked detectable Xist RNA (Ganesan et al., 2002) . We examined Xist localization in primary mammary tumors developed from a mouse strain carrying a mammary-specific disruption of Brca1 exon 11 using a Cre-LoxP approach (Brca1
Co/Co ;MMTV-Cre; Xu et al., 1999b) . We compared 14 Brca1 mutant mammary tumors to 3 Brca1 wild-type mammary tumors developed from MMTV-Neu transgenic mice (Brodie et al., 2001 ) and found no significant difference in Xist RNA localization (Figure 4 ). In 11 of 14 primary Brca1 mutant mammary tumors and all Brca1 wild-type tumors, over 90% of cells exhibited normal Xist RNA staining ( Figure 4 ; Figure S6 ). In many cells, there were multiple accumulations of Xist RNA, indicating the presence of >2 Xi chromosomes ( Figure 4A , right column). Consistent with this, the primary tumors with two or more Xist foci in the majority of cells contained three or more X chromosomes in most cells ( Figure 4A , left and middle columns; Table S2 ; data not shown). The Xist RNA-enriched domains in Brca1 mutant cells were devoid of H3K4me3 immunofluorescence, indicating that the Xist RNA signals we detected were from an Xi ( Figure S7 ; Boggs et al., 2002 ). These data demonstrate that Xist RNA can coat Xi chromosomes in primary Brca1 mutant tumor cells. Three of the fourteen primary Brca1 mutant tumors examined showed low frequencies of cells with Xist RNA (7%, 12%, and 22%; Figure 4B and data not shown). We examined the number of X chromosomes in two of these tumors. In the tumor showing 22% of cells with Xist RNA, most cells (82%) had one X chromosome, suggesting that the lack of Xist RNA staining was due to loss of the Xi ( Figure 4B ; sample 3 in Table S2 ). The other tumor had 7% of cells with Xist RNA staining and had three or more X chromosomes in 90% of cells, suggesting that the Xa was amplified in these cells (sample 2 in Table  S2 ). This loss and gain of X chromosomes in primary Brca1 mutant tumors is consistent with the general karyotypic instability described for Brca1 mutants (Weaver et al., 2002; Xu et al., 1999a) .
Analysis of cell lines derived from Brca1 mutant mammary tumors showed similar variability of Xist RNA staining, which accompanied losses and gains of X chromosomes (Figures 4C and 4D ; Table S2 ). For example, one cell line had five or more X chromosomes in more than 50% of the cells and four or more Xist RNA bodies in $40% of cells, indicating Xi gain (sample 6 in Table S2 ). One line had no detectable Xist RNA staining and a single X chromosome, indicating loss of the Xi (sample 8 in Table  S2 ). In another line, 81% of cells had three or more X chromosomes without detectable Xist RNA staining, suggesting that the Xa was amplified (sample 7 in Table S2 ). Together, our data argue that Xist RNA can properly localize to the Xi in primary Brca1 mutant tumors and cell lines. When loss of Xist RNA staining is observed, it is likely attributable to loss of the Xi, as has been documented for human cancer cell lines (Kawakami et al., 2004; Sirchia et al., 2005) .
XIST RNA Distribution in Human Breast Cancer Cell Lines
We also monitored XIST RNA distribution in the human breast cancer cell lines MCF-7 (BRCA1 WT ) and L56Br-C1 (Johannsson et al., 2003) . L56Br-C1 cells express BRCA1
Q563Stop
, a mutation that truncates over two-thirds of the C terminus of BRCA1, resulting in an unstable protein. The absence of BRCA1 in L56Br-C1 was confirmed by immunostaining and western blotting ( Figure 5A ). Despite the loss of BRCA1 expression in L56Br-C1 cells, normal XIST RNA accumulations were observed in 61% of cells ( Figures 5B and 5D ). Many cells contained two XIST-enriched nuclear domains, indicating the presence of multiple Xi chromosomes in these cells. The remaining 39% of L56Br-C1 cells displayed aberrant XIST RNA localization patterns, ranging from no XIST expression to dispersed XIST RNA particles. This aberrant XIST RNA localization could not be attributed to the loss of BRCA1, since MCF-7 cells showed normal BRCA1 expression levels and nuclear localization ( Figure 5A ) and also showed a similar proportion of cells with aberrant XIST RNA localization patterns ( Figures 5B and 5C ). Together, these analyses of human breast cancer cell lines demonstrate that cells lacking BRCA1 can exhibit normal XIST RNA localization.
X-Linked Gene Expression in Brca1 Mutant Somatic Cells and Tumors
Depletion of BRCA1 by RNAi was reported to cause infrequent reactivation of an Xi-linked GFP transgene, suggesting that this low-level reactivation may occur through loss of Xist from the Xi (Ganesan et al., 2002) . However, our data indicated that Xist RNA was normally localized in cells depleted for BRCA1 by RNAi and in most Brca1 mutant tumors. These results suggest that BRCA1 affects expression of X-linked genes in a manner independent of Xist RNA localization. We therefore tested whether mutation of Brca1 could cause changes in X-linked gene expression in a strain of Brca1 mutant mice carrying a germline deletion of full-length Brca1 (Brca1 D11/D11 ). The mutant mice died during embryonic day (E) 12-18; however, they could survive to adulthood when a copy of p53 was also deleted (Brca1 D11/D11 ;p53 Xu et al., 2001) .
We analyzed the expression levels of ten X-linked genes in different embryonic stages by real-time RT-PCR (Figure 6A) . The genes chosen for analysis were broadly distributed along the X chromosome ( Figure S8 ; Table S3 ).
Analysis of Brca1
D11/D11 and Brca1 +/D11 control embryos revealed no significant alterations in gene expression at E12, E13.5, E15.5, E16.5, and E18 ( Figure 6A and data not shown). These data indicate that the Brca1 D11/D11 mutation allows for Xist-dependent initiation of X inactivation.
Next, we compared the expression levels of X-linked genes in the mammary glands of Brca1 D11/D11 ;p53 +/À mutant and control (p53 +/À ) mice at three different stages of the mammary cycle: virgin, pregnant day 16.5, and lactation day 1. Again, we did not observe any significant alterations in the expression levels of the same ten X-linked genes analyzed in Figure 6A (data not shown). Using a cDNA microarray containing 690 X-linked genes that are expressed at these three stages of the mammary cycle of development, we found that 16 X-linked genes showed altered expression levels in Brca1
;p53
mammary glands in comparison with controls at all three time points (Table S4) . Among these 16 genes, 9 were upregulated and 7 were downregulated. These results indicate that mutation of Brca1 could affect expression of a few X-linked genes in mammary tissues. However, it is unlikely that this was caused by failure of X chromosome inactivation, as seven of the genes were downregulated and Xist RNA was expressed in all of the Brca1 mutant mammary tissues. Consistent with this, a cell line derived from Brca1 D11/D11 ;p53 +/À mammary epithelium exhibited Xist RNA localization comparable to the p53 +/À control cell line ( Figures 6C-6F ), indicating that changes in X-linked gene expression caused by mutation of Brca1 occur in a manner independent of Xist RNA localization. Finally, X-linked gene expression in six primary mammary tumors developed from Brca1
D11/D11
;p53 +/À mice were compared with normal mammary tissues obtained from the same mice using real-time PCR of the same ten X-linked genes analyzed in Figure 6A . We detected 2-to 76-fold increase in expression of some X-linked genes ( Figure 6B and data not shown), but the genes showing increased expression levels were not consistent among different tumors. Because Brca1 mutant primary tumors exhibit extensive aneuploidy, chromosome rearrangement, and amplification/loss of X chromosomes (Brodie et al., 2001; Weaver et al., 2002; Xu et al., 1999a ; Figure 4 ; Table  S2 ), it is possible that chromosome changes or other secondary effects of tumorigenesis could cause altered X-linked gene expression in a manner independent of Xist RNA.
DISCUSSION
Our studies of BRCA1 and its relationship to XIST RNA (summarized in Table 1 ) largely contradict the published findings of Ganesan et al. (2002) . We observed normal XIST/Xist RNA localization when BRCA1 was depleted by RNAi in human and mouse cells. Xist RNA accumulated properly on the Xi in the majority of Brca1 D11/D11 mutant mouse tumors and in a human BRCA1 mutant breast tumor line. Brca1 D11/D11 mutant embryos had proper X chromosome dosage compensation, indicating that Xistdependent functions during the initiation of X inactivation were not perturbed. In addition, we did not observe colocalization between BRCA1 and XIST RNA. Although we cannot account for all of the discrepancies between our data and the published findings of Ganesan et al., we feel obligated to report these results.
In their analysis of BRCA1 and XIST RNA colocalization, Ganesan et al. (2002) stated that, in all instances, colocalization referred to ''costaining of a single, large, discrete nuclear body.'' Their accompanying Figure 1 showed examples of large BRCA1 structures completely overlapping XIST RNA, a pattern reported to occur in 5%-10% of cells. In contrast, we were unable to detect convincing colocalization between BRCA1 and XIST RNA. To maximize our chances of detecting BRCA1/XIST RNA overlap, we examined the same cell lines that were reported to show colocalization of BRCA1 with XIST RNA, using the same antibodies and fixation conditions (Ganesan et al., 2002) . In >5400 total events scored, we could not find one example in which BRCA1 and XIST RNA showed significant overlap ( Figure 1 ; Table S1; Figure S2 ). Thus, BRCA1 is not a visibly enriched constituent of XIST-containing chromatin on the Xi. Instead, BRCA1 appeared as a small focus or ''patch'' next to XIST RNA in a small fraction of cells (<3%). Whether this denotes a specific relationship to Xi heterochromatin is unclear: BRCA1 also shows overlap with the active X chromosome ) and often appears in multiple foci distributed throughout the nucleus, suggestive of association with autosomes.
A recent study indicated that when a small focus or ''patch'' of BRCA1 is in the vicinity of the Xi, the Xi is undergoing replication (Chadwick and Lane, 2005) . Cells with a replicating Xi typically represent $1% of an asynchronous cell population, suggesting that the low frequency Figure S3 ). In combination, our localization data indicate that BRCA1 may associate with a component of the replicating Xi that is not coated by XIST RNA, in a manner that may be stochastic or extremely transient in a given cell population. Because our data do not indicate a role for the infrequent BRCA1-Xi association in regulating XIST RNA, the functional relevance of this BRCA1 localization pattern remains an unresolved question. It was previously argued that the HCC1937 BRCA1-deficient tumor cell line harbored a defect in XIST RNA localization that was attributable to mutant BRCA1 genotypic status (Ganesan et al., 2002) . A more plausible explanation for this observation is that HCC1937 cells do not contain an Xi. HCC1937 cells lack Barr bodies, CpG methylation of X-linked genes, and histone modifications that distinguish Xi heterochromatin, indicating that the X chromosomes present in HCC1937 cells are all transcriptionally active (Ganesan et al., 2002; Sirchia et al., 2005) . Furthermore, the X chromosomes in HCC1937 cells display extensive homozygosity, which could be attributable to loss of the Xi and amplification of the Xa in tumor progenitor cells (Sirchia et al., 2005) . This phenomenon also occurs in BRCA1
WT tumor cell lines: the T47D, MDA-MB-231, and HCC2185 breast cancer lines all lack Barr bodies, XIST expression, CpG methylation of X-linked genes, and heterozygous X chromosomes (Sirchia et al., 2005) . These BRCA1 WT lines all contain two or more X chromosomes, indicating that the presence of multiple X chromosomes in any particular cell line or tumor sample is not sufficient evidence for the presence of an Xi. Several other BRCA1 WT cell lines derived from breast, ovarian, and cervical cancers also lack an Xi (Huang et al., 2002; Kawakami et al., 2004; Wang et al., 1990) . Thus, the apparent lack of an Xi is common in female cancer cells and occurs independently of cell type or BRCA1 genotypic status.
Because there is no evidence for the presence of inactive X chromosomes in HCC1937 cells, the XIST RNA in these cells most likely arises from the XIST locus on an Xa. Previous studies have detected ectopic XIST RNA transcription from an Xa when cells are treated with inhibitors of DNA methyltransferases (Hansen, et al., 1998) . Perturbation of DNA methylation in cancer cells might therefore cause spurious XIST transcription from an Xa. It is possible that the particular aliquots of HCC1937, HCC1937+vector, and HCC1937+BRCA1 WT cells analyzed by Ganesan et al. (2002) showed an XIST RNA localization pattern that suggested a correlation with BRCA1 expression status. However, we detected variable patterns of XIST RNA distribution in different cultures of HCC1937 and derivative lines, indicating that differences in XIST RNA abundance or localization are likely due to stochastic differences in XIST promoter activity on the Xa.
It was previously reported that XIST/Xist RNA was undetectable in BRCA1/Brca1 D11/D11 mutant tumor cells (Ganesan et al., 2002) . In contrast, normal XIST/Xist RNA staining was detected in one BRCA1
WT ovarian tumor, one BRCA1 WT breast tumor, and one murine Brca1 WT mammary tumor (Ganesan et al., 2002) . However, our analysis of murine Brca1 D11/D11 primary tumors revealed proper Xist RNA localization in the majority of cells for 11 of 14 tumors. Two Brca1 D11/D11 tumor cell lines were reported to have no Xist RNA signal (Ganesan et al., 2002) , but our analysis of six more Brca1 D11/D11 tumor cell lines showed that three of them had normal Xist RNA distribution. While it is formally possible that other mutations in Brca1/BRCA1 may exhibit Xist/XIST RNA localization defects (Ganesan et al., 2002) , this is unlikely since Xist/XIST RNA localization also appeared normal upon BRCA1 knockdown and in a human BRCA1 mutant tumor cell line (Table 1 ). In addition, normal XIST RNA localization has recently been reported in a second human BRCA1 mutant tumor cell line .
Given the high levels of genomic instability seen in BRCA1 mutant tumors (Brodie et al., 2001; Tirkkonen et al., 1997; Tomlinson et al., 1998; Weaver et al., 2002; Xu et al., 1999a Xu et al., , 1999b , it is likely that tumor samples with no detectable XIST RNA may simply lack Xi chromosomes, which could have been the case in the tumors analyzed by Ganesan et al. (2002) . Indeed, we observed examples of both Brca1 D11/D11 primary tumors and cell lines containing only one X chromosome in the majority of cells. We also found examples of Brca1 D11/D11 primary tumors and cell lines that had more than one X chromosome but lacked Xist RNA. These cells are all highly aneuploid, indicating that multiple X chromosomes could have arisen by an increase in ploidy that resulted in increased numbers of both the active X chromosome and the Xi, and the subsequent loss of the Xi, as has been documented for multiple BRCA1 mutant and wild-type tumor cell lines (Sirchia et al., 2005) .
A recently published study further weakens any correlation between BRCA1 genotypic status in breast tumors and the presence of normal XIST RNA association with the Xi (Richardson et al., 2006) . Seventeen of thirty-eight BRCA1
WT basal-like (BLC) and non-BLC tumor samples lacked detectable XIST RNA staining even though the BRCA1 was wild-type (Richardson et al., 2006) . The discussion section of Richardson et al. (2006) states that ''One explanation is that, although BRCA1 is intact, BLC have developed defects in other genes involved in specific cellular pathways in which BRCA1 also plays a key role, thus leading to a phenocopy of BRCA1-deficient tumor cells.'' However, a more direct explanation for the findings of Richardson et al. (2006) is that XIST RNA/Xi defects in breast cancer occur independently of BRCA1 function. Richardson et al. (2006) also demonstrate a lack of XIST RNA staining in four human BRCA1 À/À mutant tumors. However, all four of these tumors lack markers of Xi heterochromatin and have lost heterozygosity of the X chromosome, suggesting loss of the XIST-expressing Xi in these cells. Twelve of the sporadic, basal-like tumor samples also showed a loss of heterozygous X chromosomes, demonstrating that Xi loss is not unique to BRCA1 À/À tumors. The absence of XIST RNA in these tumors therefore does not indicate a role for BRCA1 in regulating XIST RNA localization. Instead, the data presented in Richardson et al. (2006) support the interpretation that loss of XIST RNA in cancer is often due to loss of the Xi, as is well documented (Sirchia et al., 2005; Kawakami et al., 2004) and as is supported by our analysis of murine Brca1 tumors. Ganesan et al. (2002) reported that depletion of BRCA1 by RNAi caused infrequent reactivation of an Xi-linked GFP transgene and attributed this low-level reactivation to loss of Xist RNA. However, we found that Xist RNA was normally localized in most Brca1 mutant tumors and cells depleted for BRCA1 by RNAi, suggesting that BRCA1 may affect expression of X-linked genes in a manner independent of Xist. In Brca1 D11/D11 tumor samples, there were a small number of X-linked genes that were differentially expressed when compared to control samples, yet the identity of the genes varied between different tumors. Brca1 D11/D11 tumors contain variable numbers of X chromosomes and autosomes, which could cause changes in X-linked gene expression that would not be directly attributable to failure of X inactivation or Brca1 mutation. For example, a recent study reported lower levels of DNA methylation in female embryonic stem cells containing two active X chromosomes when compared with male embryonic stem cells (Zvetkova, et al., 2005) . Alteration of the Xa:autosome ratio in aneuploid cancer cells could therefore conceivably cause progressive loss of DNA methylation, leading to gene expression changes on autosomes as well as X chromosomes.
The X chromosome harbors many genes that are differentially expressed in breast tumors and other types of cancers (Jazaeri et al., 2002 (Jazaeri et al., , 2004 Spatz et al., 2004; Thakur et al., 2005) . The question of which of these genes may contribute to tumor development in BRCA1 WT or BRCA1 À/À genetic backgrounds remains unresolved.
While changes in expression of X-linked genes may contribute to tumor progression, our data indicate that these changes are not mediated by perturbation of XIST function in BRCA1 mutant cells.
EXPERIMENTAL PROCEDURES
Detailed descriptions of all experimental procedures are provided in the Supplemental Data.
Mice

Brca1
Co/Co ;p53
;MMTV-Cre (Xu et al., 1999b) , Brca1 D11/D11 ;p53
and Brca1 D11/+ , and Brca1 D11/D11 ;Chk2 À/À (Cao et al., 2006) mice were generated and genotyped as previously described. All animals were handled in accordance with the guidelines of the NIDDK Animal Care and Users Committee.
Antibodies
The antibodies employed were rabbit polyclonal anti-mouse BRCA1 antibody (BRCA1-1059; Turner et al., 2004) , rabbit polyclonal antibody to macroH2A1, mouse monoclonal antibody against g-H2AX (Upstate), monoclonal antibodies SD118, MS110, and SG11 raised against human BRCA1, and the GH118 antibody to mouse BRCA1 (Scully et al., 1997a (Scully et al., , 1997b Ganesan et al., 2002) .
Total RNA Processing, Microarray Studies, and Real-Time RT-PCR Analysis Total RNA was isolated from different stages of embryos, adult mammary glands, or primary mammary tumor tissues using the RNA Inc.) . RNA samples were processed by the NIDDK Genomics Core Laboratory at NIH and hybridized with GeneChip Mouse Genome 430 2.0 (Affymetrix, Inc.). Analysis was performed using Microsoft Excel. Real-time RT-PCR was carried out using SYBR Green PCR Master Mix (Applied Biosystems) containing AMV transcriptase and RNase inhibitors (Roche Applied Science) and a 7500 Real-Time PCR System (ABI) equipped with SDS software. HCC1937 wholecell RNA was isolated using Trizol (Invitrogen). cDNA was synthesized according to the Superscript II (Invitrogen) protocol. Quantitation was performed on an MJ Opticon thermal cycler (MJ Research) using SYBR green to detect PCR products. Primers are listed in Table S3 .
Primary Mammary Tumor Samples
Primary mammary tumor samples were cut into small pieces and cultured with 1 mg/ml type 3 collagenase in DMEM with 10% FBS and EGF and insulin overnight. Cells were then pipetted into a single-cell suspension, washed twice with medium, and cultured overnight. One hour before harvesting, cells were treated with 10 ng/ml colcemid. Chromosome spreads were prepared using methanol:acetic acid (3:1) fixation. In one instance, cryosections were used for Xist RNA-FISH analysis.
FISH and Immunofluorescence
Immunostaining was performed as described previously (Ganesan et al., 2002) . FISH, alone or in combination with immunostaining, was carried out using standard protocols . Xist/ XIST clones were labeled with SpectrumGreen-or SpectrumOrangedUTP (Vysis) or Cy3-dCTP (Amersham). For X chromosome painting, flow-sorted mouse X chromosomes were labeled by PCR using SpectrumOrange-dUTP. Hybridization was performed according to the protocol listed at http://www.riedlab.nci.nih.gov/protocols.asp.
RNA Interference
RNAi in HMEC-t cells was performed in cells stably transfected with a shRNA to BRCA1 (Jones et al., 2005) . HEK293 cells were transfected with short RNA duplexes generated from a BRCA1 dsRNA (nucleotides 2000-2580 or 3310-3800) using RNase III. shRNAs specific for mouse BRCA1 (Open Biosystems, RMM1766-9108401) or pCMS-EGFP (Clontech) were transfected into mouse mammary cancer cell line NK (MMTV-Neu transgenic mammary tumor cell line) using the MEF1 Nucleofector Kit and Nucleofector II machine (Amaxa Biosystems).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures, Supplemental References, four tables, and eight figures and can be found with this article online at http://www.cell.com/cgi/content/full/ 128/5/977/DC1/.
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